Kangchen Pharmaceutical (603590.SH) posted an advance increase. The net profit for 2025 is expected to be 145 million yuan to 175 million yuan, an increase of 243% to 315% over the previous year

Zhitongcaijing · 4d ago

Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) announced that the company expects to achieve net profit of 145 million yuan to 175 million yuan in 2025, an increase of 243% to 315% over the previous year.

Last year, the company calculated goodwill impairment preparations for the acquisition of shares in the former Tailing Pharmaceutical International Co., Ltd. (now renamed Fangheng Pharmaceutical International Co., Ltd.) in accordance with corporate accounting standards, leading to an increase in asset impairment losses. The impact of goodwill impairment preparations was not taken into account during the reporting period.